Net loss of Oxygenta Pharmaceutical reported to Rs 2.15 crore in the quarter ended March 2025 as against net profit of Rs 8.02 crore during the previous quarter ended March 2024. Sales rose 368.91% to Rs 49.47 crore in the quarter ended March 2025 as against Rs 10.55 crore during the previous quarter ended March 2024.
For the full year,net loss reported to Rs 10.30 crore in the year ended March 2025 as against net loss of Rs 3.48 crore during the previous year ended March 2024. Sales rose 175.73% to Rs 109.30 crore in the year ended March 2025 as against Rs 39.64 crore during the previous year ended March 2024.
| Particulars | Quarter Ended | Year Ended | ||||
| Mar. 2025 | Mar. 2024 | % Var. | Mar. 2025 | Mar. 2024 | % Var. | |
| Sales | 49.47 | 10.55 | 369 | 109.30 | 39.64 | 176 |
| OPM % | -3.40 | -15.26 | - | -9.15 | -24.47 | - |
| PBDT | -3.76 | -2.19 | -72 | -10.47 | -11.25 | 7 |
| PBT | -3.53 | -2.83 | -25 | -14.08 | -13.91 | -1 |
| NP | -2.15 | 8.02 | PL | -10.30 | -3.48 | -196 |
Powered by Capital Market - Live News